Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AACR 2018: St. Jude Partners With Microsoft to Create Global Genomic Database for Pediatric Cancer

By Kenny Walter | April 17, 2018

Researchers worldwide are able to interact with pediatric cancer genomic data through St. Jude Cloud. The individuals pictured are exploring interactive genomic visualizations by using ProteinPaint within St. Jude Cloud. Credit: St. Jude Children’s Research Hospital

Researchers around the globe can now access thousands of pediatric cancer genomic datasets, thanks to a new cloud-based initiative.

The St. Jude Children’s Research Hospital has launched the St. Jude Cloud—an online, publicly available data-sharing and collaboration platform—that gives researchers the world’s largest public repository of pediatric cancer genomics data.

Scott Newman, PhD, group lead for bioinformatics analysis in the St. Jude Department of Computational Biology presented St. Jude Cloud on April 15 at the 2018 American Association for Cancer Research (AACR) Annual Meeting. The cloud was developed as a collaboration between St. Jude, DNAnexus and Microsoft to provide accelerated data mining, analysis and visualization capabilities in a secure cloud-based environment.

“Sharing research and scientific discoveries is vital to advancing cures and saving lives, especially in rare diseases like pediatric cancer,” James Downing, MD, the St. Jude president and chief executive officer, said in a statement. “St. Jude has shared data and resources since its founding, and collaboration with researchers across the world is at the core of our mission. St. Jude Cloud offers researchers access to genomics data and analysis tools that will drive faster progress toward cures for catastrophic diseases of childhood.”

The new cloud will allow scientists to comb through more than 5,000 whole-genome, 5,000 whole-exome and 1,200 RNA-Seq datasets from more than 5,000 pediatric cancer patients and survivors. The amount of datasets—which are stored on Microsoft Azure—are expected to double by next year.

The majority of the data has been derived from the St. Jude—Washington University Pediatric Cancer Genome Project, designed to understand the genetic origins of childhood cancers, the Genomes for Kids clinical trial, focused on moving whole genome sequencing into the clinic, and the St. Jude Lifetime Cohort study (St. Jude LIFE), which conducts comprehensive clinical evaluations on thousands of pediatric cancer survivors throughout their lives.

The cloud also features a collection of bioinformatics tools that aid both experts and non-specialists to gain novel insights from the data. The tools include validated data analysis pipelines and interactive visualization tools to make it easier to utilize large datasets. The data can be shared privately within the platform.

Researchers will be able to explore the data or their own results using interactive visualizations powered by ProteinPaint—a genomic visualization engine created at St. Jude that allows users to navigate through the genome and identify genetic changes linked to cancer development.

A St. Jude scientist was able to use the St. Jude Cloud to replicate, in just a few days, experimental findings that originally took the research team more than two years to make.

“St. Jude Cloud is a powerful resource to drive global research and discovery forward,” Jinghui Zhang, PhD, chair of the St. Jude Department of Computational Biology and co-leader of the St. Jude Cloud project, said in a statement. “Providing genomic sequencing data to the global research community and making complex computational analysis pipelines easily accessible will lead to progress in eradicating childhood cancer.

“St. Jude has been committed to sequencing and understanding pediatric cancer genomes for nearly a decade, and we will continue to generate and share data with the research community in the future.”


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE